Francis M. Grant

Francis M. Grant

Auto-generated profile, based on publicly available information

Francis M. Grant

Immunology Programme, Babraham Institute, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in Science Immunology
Verified
Journal Article
Open access
SWSarah K. Whiteside
Sarah K. Whiteside
FGFrancis M. Grant
Francis M. Grant
GAGiorgia Alvisi
Giorgia Alvisi
JCJames Clarke
James Clarke
LTLeqi Tang
Leqi Tang
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T (T reg ) cells contribute to immune homeostasis but suppress immune responses to cancer. Strategies to disrupt T reg cell–mediated cancer immunosuppression have been met with limited clinical success, but the underlying mechanisms for treatment failure are poorly understood. By modeling T reg cell–targeted immunotherapy in mice, we find that CD4 + Foxp3 − conventional T (T conv ) cells acquire suppressive function upon depletion of Foxp3 + T reg cells, limiting therapeutic efficacy. Foxp3 − T conv cells within tumors adopt a T reg cell–like transcriptional profile upon ablation of T reg cells and acquire the ability to suppress T cell activation and proliferation ex vivo. Suppressive activity is enriched among CD4 + T conv cells marked by expression of C-C motif receptor 8 (CCR8), which are found in mouse and human tumors. Upon T reg cell depletion, CCR8 + T conv cells undergo systemic and intratumoral activation and expansion, and mediate IL-10–dependent suppression of antitumor immunity. Consequently, conditional deletion of Il10 within T cells augments antitumor immunity upon T reg cell depletion in mice, and antibody blockade of IL-10 signaling synergizes with T reg cell depletion to overcome treatment resistance. These findings reveal a secondary layer of immunosuppression by T conv cells released upon therapeutic T reg cell depletion and suggest that broader consideration of suppressive function within the T cell lineage is required for development of effective T reg cell–targeted therapies.

30 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CICharlotte J. Imianowski
Charlotte J. Imianowski
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa Lozano
Teresa Lozano
AEAlexander C. Evans
Alexander C. Evans
JBJayme D. Benson
Jayme D. Benson
RRRahul Roychoudhuri
Rahul Roychoudhuri
Natural killer (NK) cells are critical to immune surveillance against infections and cancer. Their role in immune surveillance requires that NK cells are present within tissues in a quiescent state. Mechanisms by which NK cells remain quiescent in tissues are incompletely elucidated. The transcriptional repressor BACH2 plays a critical role within the adaptive immune system, but its function within innate lymphocytes has been unclear. Here, we show that BACH2 acts as an intrinsic negative regulator of NK cell maturation and function. BACH2 is expressed within developing and mature NK cells and promotes the maintenance of immature NK cells by restricting their maturation in the presence of weak stimulatory signals. Loss of BACH2 within NK cells results in accumulation of activated NK cells with unrestrained cytotoxic function within tissues, which mediate augmented immune surveillance to pulmonary cancer metastasis. These findings establish a critical function of BACH2 as a global negative regulator of innate cytotoxic function and tumor immune surveillance by NK cells.